Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Identify headache made more frequent by regular acute-medicine exposure, explain the diagnosis without blame, and support withdrawal while treating the underlying primary headache disorder.
Medication-overuse headache is a secondary headache arising in a person with a pre-existing headache disorder during regular overuse of acute or symptomatic treatment. The clinical picture is often a gradual increase from discrete migraine or tension-type attacks to near-daily or daily pain, with acute medicines becoming less reliable. Diagnostic thresholds are class-specific: triptans, ergots, opioids and combination analgesics on at least 10 days per month, or simple analgesics such as paracetamol, aspirin and NSAIDs on at least 15 days, for more than 3 months, in someone with headache on at least 15 days monthly. Exposure to several classes can meet a multiple-drug threshold even when no single class seems excessive. The diagnosis is usually clinical and can be made prospectively while outcome after withdrawal clarifies causality.
History should reconstruct a typical month, not ask merely whether the person takes 'a lot'. Count headache days, migraine-feature days and days of each medicine, including caffeine combinations, opioid-containing prescriptions and remedies taken for neck or other pain. Establish dose escalation, morning use, anticipatory use and fear of being unable to work. Review sleep, mood, dependence, gastrointestinal or renal harm and the adequacy of prior acute and preventive care. Perform a neurological and funduscopic examination and rescreen for secondary features because chronic exposure does not immunise someone against a new intracranial disorder. Imaging is not routinely required when the phenotype is secure and examination is normal.
Migraine and tension-type headache provide the usual biological substrate on which frequent rescue-medicine exposure increases headache frequency.
Triptans, opioids, ergots, combination analgesics and simple analgesics carry differing overuse patterns when taken regularly across many treatment days.
Delayed access to prevention, fear of losing function, repeated large prescriptions and unrecognised over-the-counter combinations can sustain exposure without intentional misuse.
Frequent acute treatment repeatedly alters trigeminovascular and descending pain-control systems in a person already susceptible to primary headache.
Pain networks become more responsive and less able to filter ordinary sensory input, increasing background and attack-related headache.
Temporary relief is followed by recurrence or withdrawal pain, prompting further dosing and reducing confidence in non-drug or preventive strategies.
Headache on at least 15 days monthly is the necessary background frequency; lower frequency does not meet medication-overuse-headache criteria even if prescribing is unsafe.
Use of triptans, opioids, ergot derivatives or combination analgesics on 10 or more days each month for over 3 months reaches the class threshold.
Paracetamol, aspirin or NSAID use on at least 15 days monthly for over 3 months can maintain medication-overuse headache.
Formerly discrete migraine or tension-type episodes may become more frequent, less predictable and less responsive, while still showing intermittent features of the underlying disorder.
Escalating strong opioid use, withdrawal between doses, multiple sedatives, severe mental illness or previous failed detoxification signals need for specialist support and sometimes inpatient care.
A new focal sign, papilloedema, systemic illness, abrupt peak or positional change is not accounted for by overuse and requires an independent urgent work-up.
Frequent migraine can occur without overuse; a medicine-day history establishes whether rescue exposure is an important modifiable contributor.
New neurological signs, systemic disease, pressure features or abrupt change require investigation and should not be explained away by regular analgesic use.
Bilateral pressure without migraine-associated symptoms may be chronic tension-type headache, with or without a superimposed overuse component.
Caffeine, opioid or other withdrawal can cause short-lived headache linked to cessation rather than the established chronic overuse syndrome.
Increasing headache days impair work, sleep, caring roles and mood and can make the original episodic disorder difficult to recognise.
Opioid and combination-product use may create physiological dependence, difficult withdrawal and escalating healthcare use during repeated exposure.
Repeated analgesic exposure can cause gastrointestinal bleeding, kidney injury, liver toxicity or cardiovascular harm according to the medicine and comorbidity.
Without an effective acute limit and preventive plan, renewed frequent rescue use can restore the sensitisation cycle after initial improvement.
Three tablets on one day count differently from single tablets on three days because repeated exposure across the month is the diagnostic pattern.
A patient alternating triptan, ibuprofen and a caffeine combination may underestimate total acute-treatment exposure when each brand is considered alone.
Temporary deterioration after withdrawal does not mean the diagnosis or plan is wrong; anticipatory explanation and planned contact improve persistence.
Treating the underlying migraine while removing overused rescue medicines may improve feasibility, provided the preventive is selected and reviewed on its own merits.
Describing adaptation rather than blame respects why the patient sought relief and makes shared withdrawal more credible than accusing them of causing their pain.
Asking how many tablets are taken but not how many days per month are exposed, then missing the defining frequency pattern.
Counting prescribed triptans while ignoring pharmacy analgesics, caffeine combinations or opioid medicines used for another pain condition.
Giving an unsupported abrupt-stop instruction to someone dependent on strong opioids or sedatives without assessing withdrawal and comorbidity risk.
Replacing the withdrawn medicine with another acute drug used just as frequently and perpetuating the same cycle under a different name.
Assuming all chronic headache is overuse and failing to investigate new papilloedema, focal signs, systemic features or thunderclap pain.
Completing one month of withdrawal without a durable acute-treatment limit, prevention review or prescription plan to reduce relapse.
Your practice draft is saved in this browser.
A patient with underlying tension-type headache now has headache on 20 days each month and has taken paracetamol on 18 days monthly for 5 months. Which interpretation is most appropriate?
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
NICE recommends withdrawing all overused headache medicines for at least 1 month, advising that headache commonly worsens before improving and nausea, restlessness or sleep disturbance can occur. For most triptan, simple-analgesic and combination-analgesic overuse, abrupt outpatient withdrawal with information and support is appropriate. Strong opioids and complex dependence require specialist planning because withdrawal risks, comorbidity and safeguarding differ; an unmodified abrupt instruction may be unsafe. Arrange contact during the difficult first phase and a formal review after 4–8 weeks. A preventive for the underlying migraine or tension-type disorder may be offered alongside withdrawal, particularly when attack burden is high. Once the cycle improves, create a specific acute plan with use limits and early preventive review so relapse is not treated by renewed unrestricted supply.